Skip to main content
. Author manuscript; available in PMC: 2021 Aug 24.
Published in final edited form as: ACS Chem Neurosci. 2020 Jul 17;11(15):2231–2242. doi: 10.1021/acschemneuro.0c00170

Fig. 1: Pharmacokinetic studies of KVA-D-88 in vivo.

Fig. 1:

KVA-D-88 was synthesized and administered into mice by either i.v. (1 mg/kg) or oral approach (10 mg/kg). The blood was then collected for determining its pharmacokinetic parameters. (A) Representative molecular structure of KVA-D-88. (B) PK parameters of KVA-D88 in mice with either i.v. injections or oral approach. (C) The concentration-time curve of KVA-D-88 in vivo after either i.v. injections or oral approach.